Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. RaySearch Laboratories AB's Revenue for the
three
months ended in Mar. 2026 was kr290 Mil. RaySearch Laboratories AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr93 Mil.
Hence, RaySearch Laboratories AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.11.
RaySearch Laboratories AB (CHIX:RAYBs) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
RaySearch Laboratories AB Receivables Turnover Related Terms
RaySearch Laboratories AB Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB Receivables Turnover Chart
CHIX:RAYBS vs VEEV, BTSG, TEM: Receivables Turnover Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (CHIX:RAYBS) has a Receivables Turnover of 3.11 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RaySearch Laboratories AB and its competitors. According to the industry distribution chart, RaySearch Laboratories AB ranks #311 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 47.2%.
Is RaySearch Laboratories AB's Receivables Turnover too high?
RaySearch Laboratories AB's current Receivables Turnover is 3.11. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. RaySearch Laboratories AB's value of 3.11 is 59.9% below this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #311 out of 659 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Receivables Turnover compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #311 out of 659 companies for Receivables Turnover. This puts RaySearch Laboratories AB in the upper half of its industry. The industry median Receivables Turnover is 7.75. RaySearch Laboratories AB's value of 3.11 is 59.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Receivables Turnover of 3.11 is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Receivables Turnover is 3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr181.82, compared to a current price of kr234.70 — trading 29.1% above its estimated fair value. The current Receivables Turnover is 3.11 and 59.9% below the Healthcare Providers & Services industry median of 7.75. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Receivables Turnover is 3.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 29.1% above its estimated GF Value™ of kr181.82.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for CHIX:RAYBS:
Receivables Turnover: 3.11
GF Value™: kr181.82 vs. price of kr234.70 (29.1% above fair value)
Industry Position: 59.9% below the Healthcare Providers & Services median (#311 of 659)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
